登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Heart Rhythm，6月28日，Effects of Hydroxychloroquine Treatment on QT Interval》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-06-29

  • Effects of Hydroxychloroquine Treatment on QT Interval

    Author links open overlay panelMatthewHooksMDaBradleyBartMDabOrlyVardenyPharmD, MSacAndersWestanmoPharmD, MBAdSelçukAdabagMD, MSab

    Show more

    https://doi.org/10.1016/j.hrthm.2020.06.029

    Abstract

    Background

    Hydroxychloroquine (HCQ) has been promoted as a potential treatment for COVID-19 but there are safety concerns.

    Objectives

    To determine the effect of HCQ treatment on QT interval

    Methods

    We retrospectively studied the electrocardiograms of 819 patients treated with HCQ for rheumatologic diseases from 2000 to 2020. The primary outcome was corrected QT (QTc) interval, by Bazett formula, during HCQ therapy.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S1547527120306287
15浏览量
原文链接
相关报告

  • 《6月28日_羟基氯喹对QT间期的影响》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-29
    • 信息名称：羟基氯喹对QT间期的影响 1.时间：2020年6月28日 2.机构或团队：明尼苏达大学、明尼阿波利斯VA医疗保健系统 3.事件概要： 明尼苏达大学等机构在Heart Rhythm发表论文“Effects of Hydroxychloroquine Treatment on QT Interval”。 羟氯喹（HCQ）已被推广为COVID-19的潜在治疗药物，但仍存在安全问题。因此，文章回顾性研究了2000年至2020年819例因风湿病接受HCQ治疗的患者的心电图，主要结果是校正QT（QTc）间隔。平均年龄64.0（±10.9）岁，男性734例（90%），HCQ的中位剂量和持续时间分别为400mg/天和1006（471-2075）天。治疗后平均QTc为430.9（±31.8）msec，55例（7%）患者QTc 470-500msec，12例（1.5%）QTc>500msec。慢性肾病（CKD）、房颤（AF）史和心力衰竭是延长QTc的独立危险因素。在5.97年（3.33-10.11）年的随访中，269例（33%）患者死亡。在HCQ治疗期间，QTc>470msec与更高的死亡风险相关，但在多变量分析中没有。羟基氯喹在相当一部分患者中与QT延长有关，CKD、房颤和心力衰竭患者QT延长的风险更高。 4.附件： 原文链接：https://www.sciencedirect.com/science/article/pii/S1547527120306287
    5浏览量
    原文链接

  • 《Nature，4月24日，The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-25
    • The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin Ehud Chorin, Matthew Dai, Eric Shulman, Lalit Wadhwani, Roi Bar-Cohen, Chirag Barbhaiya, Anthony Aizer, Douglas Holmes, Scott Bernstein, Michael Spinelli, David S. Park, Larry A. Chinitz & Lior Jankelson Nature Medicine (2020) To the Editor — The SARS-CoV-2 pandemic has caused more than 1.6 million positive cases and more than 95,000 confirmed deaths as of 10 April 2020 (ref. 1). Although there are no approved drugs to prevent or treat SARS-CoV-2 infection2, a recent report suggested that the combination of hydroxychloroquine and azithromycin (HY/AZ) may have a favorable effect on the clinical outcomes and viral loads of infected patients3; this resulted in massive adoption of the regimen by clinicians worldwide. However, both medications have been independently shown to increase the risk in other populations for QT-interval prolongation, drug-induced torsades de pointes (a form of polymorphic ventricular tachycardia) and drug-induced sudden cardiac death.
    18浏览量
    原文链接